Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ImmunoGen, Inc.    IMGN

Delayed Quote. Delayed  - 05/27 09:59:59 pm
5.66 USD   +0.18%
05/18 IMMUNOGEN : Reports Efficacy and Safety Data from a 46-Patient Cohor..
05/12 IMMUNOGEN : Announces Initiation of Clinical Testing of First-in-Cla..
05/12 IMMUNOGEN : Reports Third Quarter Fiscal Year 2016 Financial Results..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period June 201320142015201620172018
Sales35,559,985,569,265,079,2
Operating income (EBITDA)-68,4-66,9-54,4-114-125-126
Operating profit (EBIT)-73,0-71,5-59,9-113-129-120
Pre-Tax Profit (EBT)-72,8-----
Net income-72,8-71,4-60,7-132-152-144
P/E ratio-19,1-14,3-20,3-3,71-3,47-3,81
EPS ( $ )-0,87-0,83-0,71-1,53-1,63-1,49
Dividend per Share ( $ )------
Yield------
Reference price ( $ )16.5911.8514.385.665.665.66
Announcement Date08/02/2013
10:30am
08/01/2014
10:30am
07/31/2015
10:30am
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period June 201320142015201620172018
Debt---19,211990,2
Finance195142278---
Operating income (EBITDA)-68,4-66,9-54,4-114-125-126
Leverage
(Debt/EBITDA)
----0,17x-0,95x-0,72x
Capital Expenditure3,778,187,4315,216,617,5
Book Value Per Share (BVPS)1,44 $0,88 $0,41 $-0,85 $-1,96 $-1,61 $
Cash Flow per Share-0,72 $-0,63 $-0,64 $-1,32 $--
Announcement Date08/02/2013
10:30am
08/01/2014
10:30am
07/31/2015
10:30am
---
Balance Sheet Analysis
Assessed data source :
© 2016 Thomson Reuters
Advertisement
Financial Ratios

Size 2016e 2017e
Capitalization 493 M$ -
Entreprise Value (EV) 512 M$ 611 M$
Valuation 2016e 2017e
P/E ratio (Price / EPS)
Capitalization / Revenue 7,12x 7,58x
EV / Revenue 7,40x 9,41x
EV / EBITDA -4,48x -4,91x
Yield (DPS / Price) - -
Price to book (Price / BVPS) -6,66x -2,89x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) -164% -198%
operating Leverage (Delta EBIT / Delta Sales) -4,66x -2,22x
Net Margin (Net Profit / Revenue) -191% -235%
ROA (Net Profit / Asset) -53,0% -
ROE (Net Profit / Equities) 2 183% -
Rate of Dividend - -
Balance Sheet Analysis 2016e 2017e
CAPEX / Sales   22,0% 25,6%
Cash Flow / Sales -166% -
Capital Intensity (Assets / Sales) 3,60x -
Financial Leverage (Net Debt / EBITDA) -0,17x -0,95x
Price Earning Ratio Help 
The blue ligne is the average P/E ratio (without estimates)
EPS & Dividend